Huayuan Zhu, MD

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, China (People's Republic)

Huayuan Zhu,M.D. & Ph.D.

Associate Chief Physician
Dept. of Hematology
The first Affiliated Hospital with Nanjing Medical University
Jiangsu Province Hospital
Nanjing
China


2016-2022 Associate Chief Physician, Dept. of Hematology, JiangSu Province Hospital;
2016-2017 Postdortoral Fellow, Dept. of cancer biology, Lerner Research Institute, Cleveland Clinic.
2012-2015 Attending Doctor, Dept. of Hematology, JiangSu Province Hospital;
E-mail: huayuan.zhu@hotmail.com


Poster(s):

• 1002 - m6A-modified circTET2 interacting with HNRNPC regulates fatty acid oxidation to promote the proliferation of chronic lymphocytic leukemia

• 1102 - Integrating Multi-Omics to Reveal the Heterogeneous Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance

• 1103 - Single-cell RNA sequencing Reveals the Spatial Heterogeneity in BTKi-Resistant Richter Transformation Patients

• 1128 - Single-center study of COVID-19 infection in patients with chronic lymphocytic leukemia

• 1131 - Performance of a novel 8-color flow cytometry panel in the detection of minimal residual disease assessment of chronic lymphocytic leukemia

• 1145 - The role of 18F-FDG PET-CT in Richter Transformation and accelerated CLL

• 1149 - Ibrutinib induces cardiac arrhythmia by targeting CaV1.2 calcium channel

• 1209 - Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort

• 1228 - Single center report on cohort of patients relapsed on Bruton Tyrosine Kinase inhibitors (BTKi)